Immunome Inc. (IMNM)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$582.9M
Cash & Equivalents
$58.6M
Quarterly Burn Rate
30 mo
Est. Cash Runway
$2,504M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04871282 A Study of AL102 in Patients With Progressing Desmoid Tumors PHASE3 Active Not Recruiting 198

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IMNM.

SEC EDGAR Filings

All SEC filings for Immunome Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.